Literature DB >> 6688572

LAGRAN program for area and moments in pharmacokinetic analysis.

M L Rocci, W J Jusko.   

Abstract

A computer program is described for examination of areas (AUC) and moments of serum concentration vs time data using the Lagrange technique alone or in conjunction with linear or log-trapezoidal methods. The suitability of the Lagrange polynomial approximations to the experimental data during AUC computation is possible through output of interpolated values between consecutive data points. Ill-fitting AUC's between any data points can be replaced with values generated by either trapezoidal method. Along with the partial and total AUC and moment, the program generates model-independent pharmacokinetic parameters such as plasma clearance, terminal slope, half-life, volume of distribution at steady-state, mean residence time, and variance of the residence time.

Mesh:

Substances:

Year:  1983        PMID: 6688572     DOI: 10.1016/0010-468x(83)90082-x

Source DB:  PubMed          Journal:  Comput Programs Biomed        ISSN: 0010-468X


  129 in total

1.  Tolerance and pharmacokinetic interactions of rifabutin and azithromycin.

Authors:  R Hafner; J Bethel; H C Standiford; S Follansbee; D L Cohn; R E Polk; L Mole; R Raasch; P Kumar; D Mushatt; G Drusano
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Variability of the model-independent AUC: the one sample per individual case.

Authors:  W Jawień
Journal:  J Pharmacokinet Biopharm       Date:  1999-08

3.  Optimum numerical integration methods for estimation of area-under-the-curve (AUC) and area-under-the-moment-curve (AUMC).

Authors:  R D Purves
Journal:  J Pharmacokinet Biopharm       Date:  1992-06

4.  Safety and pharmacokinetics of rimantadine small-particle aerosol.

Authors:  R L Atmar; S B Greenberg; J M Quarles; S Z Wilson; B Tyler; S Feldman; R B Couch
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

5.  Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.

Authors:  H Cheng; J A Leff; R Amin; B J Gertz; M De Smet; N Noonan; J D Rogers; W Malbecq; D Meisner; G Somers
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

6.  Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors.

Authors:  Ramesh K Ramanathan; Merrill J Egorin; Charles Erlichman; Scot C Remick; Suresh S Ramalingam; Cynthia Naret; Julianne L Holleran; Cynthia J TenEyck; S Percy Ivy; Chandra P Belani
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

7.  Physiological pharmacokinetic model of adriamycin delivered via magnetic albumin microspheres in the rat.

Authors:  J M Gallo; C T Hung; P K Gupta; D G Perrier
Journal:  J Pharmacokinet Biopharm       Date:  1989-06

8.  A high-performance liquid chromatographic assay for CI-973, a new anticancer platinum diamine complex, in human plasma and urine ultrafiltrates.

Authors:  W W Bullen; L D Andress; T Chang; L R Whitfield; M L Welch; R A Newman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Nonlinear pharmacokinetics and interconversion of prednisolone and prednisone in rats.

Authors:  M L Huang; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

10.  Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats.

Authors:  P Mojaverian; M L Rocci; C L Saccar; P H Vlasses; R K Ferguson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Apr-Jun       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.